Health and industrial sciences company PerkinElmer Inc. said Monday it acquired the German firm chemagen Biopolymer-Technologie AG to improve its molecular diagnostics market offerings. Terms of the deal were not disclosed.
PerkinElmer, which is based in Waltham, Mass., said in a statement chemagen AG is a "key player" in the field of automated nucleic acid isolation, and the deal will give it "robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market." The deal will help applications like large-scale pathogen detection in blood banking and tissue rejection analysis.
PerkinElmer also said it has worked with chemagen for years and the company is a natural fit with its business.